The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

James Stillman Hanson net worth and biography

James Hanson Biography and Net Worth

General Counsel of G1 Therapeutics

Mr. Hanson joined G1 as General Counsel in 2018, and leads the legal, compliance and quality functions at the company. Previously, Mr. Hanson served as Associate General Counsel and Vice President at IQVIA, where he led the Quintiles legal team in the merger of Quintiles and IMS Health to create QuintilesIMS (now IQVIA). In prior positions at Quintiles, Mr. Hanson negotiated strategic contracts, represented Quintiles in its initial public offering and was responsible for its public company securities reporting. Before joining Quintiles in 2010, he practiced corporate law, including merger and acquisitions, commercial contracting, securities reporting and corporate governance at Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, LLP, a Raleigh, North Carolina law firm.

Mr. Hanson is admitted to the North Carolina state bar. He earned his J.D. from the University of North Carolina School of Law and a B.A. in Economics and History from Wake Forest University.

What is James Stillman Hanson's net worth?: The estimated net worth of James Stillman Hanson is at least $15,960.00 as of September 4th, 2020. Mr. Hanson owns 4,000 shares of G1 Therapeutics stock worth more than $15,960 as of April 24th. This net worth approximation does not reflect any other assets that Mr. Hanson may own. Learn More about James Stillman Hanson's net worth.
How do I contact James Stillman Hanson?: The corporate mailing address for Mr. Hanson and other G1 Therapeutics executives is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. G1 Therapeutics can also be reached via phone at (919) 213-9835 and via email at [email protected]. Learn More on James Stillman Hanson's contact information.
Has James Stillman Hanson been buying or selling shares of G1 Therapeutics?: James Stillman Hanson has not been actively trading shares of G1 Therapeutics during the past quarter. Most recently, James S. Hanson sold 1,445 shares of the business's stock in a transaction on Wednesday, January 5th. The shares were sold at an average price of $10.61, for a transaction totalling $15,331.45. Learn More on James Stillman Hanson's trading history.
Who are G1 Therapeutics' active insiders?: G1 Therapeutics' insider roster includes John Bailey, Jr. (CEO), James Hanson (General Counsel), Rajesh Malik (Insider), and Mark Velleca (Director). Learn More on G1 Therapeutics' active insiders.
Are insiders buying or selling shares of G1 Therapeutics?: In the last year, insiders at the sold shares 10 times. They sold a total of 110,255 shares worth more than $397,880.45. The most recent insider tranaction occured on March, 18th when CFO John W V Umstead sold 6,547 shares worth more than $19,771.94. Insiders at G1 Therapeutics own 8.2% of the company. Learn More about insider trades at G1 Therapeutics.
Information on this page was last updated on 3/18/2024.

James Stillman Hanson Insider Trading History at G1 Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/5/2022	Sell	1,445	$10.61	$15,331.45
9/4/2020	Buy	1,000	$14.95	$14,950.00	4,000
12/26/2018	Buy	1,000	$18.25	$18,250.00

James Stillman Hanson Buying and Selling Activity at G1 Therapeutics

G1 Therapeutics Company Overview

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Today's Range

Now: $3.99

$3.94

$4.24

50 Day Range

MA: $3.69

$2.15

$4.88

2 Week Range

Now: $3.99

$1.08

$5.00

Volume

343,795 shs

Average Volume

1,300,499 shs

Market Capitalization

$208.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73